Patent ID: 11857617
Assignee: TOPELIA AUST LIMITED (652 771 670)
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method for treating, ameliorating, decreasing the chances of having any adverse effects from, decreasing the severity of adverse effects from a coronavirus infection, comprising administering to a subject or an individual in need thereof:
(a) an anti-viral drug combination capable of killing a causative agent of the infection, or inhibiting the ability of the causative agent of the infection to replicate or become infectious or cause pathology in the subject or the individual in need thereof
wherein the anti-viral drug combination comprises:
(i) 1R,2S5S)-N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, or a compound having the following structure and molecular weight:, (ii) ritonavir, and
(iii) a drug combination comprising
(1) ivermectin,
(2) doxycycline, and
(3) zinc; and,

(b) a live, inactivated or attenuated causative agent of the infection,
wherein at least one dosage of the anti-viral drug combination is administered 1 or more days before, or on the day of, and/or is administered 1 or more days after, a first dose of the live, inactivated or attenuated causative agent of the infection.